Prostate Cancer Prostatic Dis. 2013 Jul 30. doi: 10.1038/pcan.2013.20. [Epub ahead of print]
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials.
Source
Department of Radiology, Oncology and Human Pathology, Oncology Unit B, Sapienza University of Rome, Rome, Italy.Abstract
Background:About
20% of patients with prostate cancer have an ECOG performance status
(PS) 2 at diagnosis. We investigate if current treatment options for
castration-resistant prostate cancer (CRPC) may decrease the risk of
death even in patients with ECOG PS of 2.Methods:PubMed was reviewed for
phase III randomized trials in patients with CRPC progressed after
docetaxel chemotherapy. Characteristics of each study and the relative
hazard ratio (HR) for overall survival and 95% confidence interval (CI)
were collected. Summary HR was calculated using random- or fixed-effects
models depending on the heterogeneity of included studies.Results:A
total of 3,149 patients was available for meta-analysis. In the overall
population, the experimental treatments decrease the risk of death by
31% (HR=0.69; 95% CI: 0.63-0.76; P<0 .001="" 0.48-1.37="" 0.52-0.99="" 0.56-0.98="" 0.62-0.76="" 1="" 2013="" 26="" 290="" 2="" 30="" 31="" 95="" a="" abiraterone="" activity="" advance="" and="" believe="" benefit="" but="" by="" cancer="" chemotherapy="" ci:="" compared="" confirmed="" controls="" crpc="" death="" decreased="" disease="" docetaxel="" doi:10.1038="" ecog-ps="2" enzalutamide="" even="" experimental="" first="" for="" had="" hormonal="" in="" is="" july="" not="" of="" online="" or="" p="" patients="" pcan.2013.20.="" poor="" previously="" prostatic="" ps.prostate="" publication="" reduced="" reduction="" reporting="" risk="" second-line="" setting="" similar="" stratified="" study="" sub-group.="" the="" therapies:="" this="" total="" treated="" treatment="" treatments="" type="" was="" were="" when="" with="">
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου